Patents Assigned to Kinki University
-
Patent number: 10449070Abstract: The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.Type: GrantFiled: August 7, 2014Date of Patent: October 22, 2019Assignees: Kinki University, OTSUKA PHARMACEUTICAL CO., LTD.Inventor: Yoshimasa Ito
-
Publication number: 20190177682Abstract: Provided are a novel cultivation method and a storage method that are suitable for storing bacteria belonging to the genus Collimonas for a long period of time. The cultivation method for bacteria belonging to the genus Collimonas is characterized in that bacteria belonging to the genus Collimonas are cultivated in a sealed state on a culture medium that includes a rice bran culture medium and/or a soy pulp culture medium. The storage method for bacteria belonging to the genus Collimonas is characterized in that the cultivated bacteria belonging to the genus Collimonas are stored at room temperature.Type: ApplicationFiled: December 7, 2018Publication date: June 13, 2019Applicants: NEW ENVIRONMENTAL TECHNOLOGY COUNCIL, KINKI UNIVERSITYInventors: Takashi ANO, Toichiro HIROSE
-
Publication number: 20190077767Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represType: ApplicationFiled: January 12, 2017Publication date: March 14, 2019Applicants: Nippon Chemiphar Co., Ltd., Kinki UniversityInventors: Hiroto TANAKA, Isao OOI, Yuzo MOGI, Masaaki HIROSE, Tsuyoshi ENDO, Toru OGAWA, Atsufumi KAWABATA
-
Patent number: 10215225Abstract: In a power-transmitting mechanism with rolling-element bearing according to the present invention, an inner ring has plural inner ring members disposed in series in an axial direction, an outer ring has plural outer ring members respectively cooperating with the plural inner ring members. Plural rolling elements are disposed between the cooperating inner ring members and outer ring members. A retainer has plural partitions retaining the plural rolling elements at predetermined intervals in the circumferential direction such that rolling elements disposed between one pair of cooperating inner ring and outer ring members and rolling elements disposed between another pair of cooperating inner ring and outer ring members orbit the corresponding inner ring members in a synchronized manner, and a connector connecting the plural partitions such that the plural partitions integrally rotate around an axis.Type: GrantFiled: March 24, 2017Date of Patent: February 26, 2019Assignees: KANZAKI KOKYUKOKI MFG. CO., LTD., KINKI UNIVERSITYInventors: Hiroshi Sugimoto, Hajimu Imanaka, Hiroshi Tottori, Yasuyoshi Tozaki
-
Patent number: 10155804Abstract: To provide a differentiation-inducing composition and a method for producing the differentiation-inducing composition, the present disclosure describes use of a degradation product containing at least a portion of the triple helical domain of collagen or atelocollagen.Type: GrantFiled: April 30, 2015Date of Patent: December 18, 2018Assignee: Kinki UniversityInventors: Koichi Morimoto, Saori Kunii, Ei Yamamoto, Hiroyuki Ito, Yoshinori Kuboki
-
Publication number: 20180285521Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient has not been available. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.Type: ApplicationFiled: September 23, 2016Publication date: October 4, 2018Applicants: YAKULT HONSHA CO., LTD., KINKI UNIVERSITYInventors: Kazuto NISHIO, Yoshihiko FUJITA
-
Publication number: 20180200554Abstract: A CT value controller includes a storage means, an input means, and a computing means. The storage means stores a function expressing a relative humidity and a CT value regarding a degradation degree of an anticancer agent, an assumed relative humidity, and a CT setting. The input means inputs a measured relative humidity and a measured ozone concentration at a time of degradation treatment of the anticancer agent. The computing means calculates a corrected CT value increment based on a difference between the measured relative humidity and the assumed relative humidity at every input of the relative humidity and the ozone concentration by using the function. The computing means determines a termination of the degradation treatment of the anticancer agent when an integrated CT value of the corrected CT value increments reaches the CT setting.Type: ApplicationFiled: March 14, 2018Publication date: July 19, 2018Applicants: TAMURA TECO CO., LTD., KINKI UNIVERSITYInventors: Kozo TAMURA, Yoshiyuki FUKUDA, Shunji ISHIWATA, Atsushi TAGA
-
Patent number: 10004932Abstract: There are provided an anticancer agent degradation method for protecting medical professionals from exposure to an anticancer agent externally scattered in, for example, a safety cabinet or prescription laboratory, during drug preparation or other circumstance, and an anticancer agent degradation apparatus for use with this anticancer agent degradation method. Anticancer agent flyoff in a safety cabinet, etc. is degraded by exploiting an action of ozone-containing air humidified by humidifying means. A relative humidity of humidified ozone-containing air is preferably greater than or equal to 80%. In controlling degradation treatment on the basis of CT values, a difference between expected humidity and measured humidity is reflected in an increment of CT value to understand the progress of anticancer agent degradation properly.Type: GrantFiled: June 18, 2014Date of Patent: June 26, 2018Assignees: TAMURA TECO CO., LTD., KINKI UNIVERSITYInventors: Kozo Tamura, Yoshiyuki Fukuda, Shunji Ishiwata, Atsushi Taga
-
Publication number: 20180027748Abstract: The purpose of the present invention is: to produce a metabolite capable of improving drought tolerance of a plant to the same level as that achieved by abscisic acid, from a microorganism other than a microorganism that is known to be capable of producing abscisic acid; and to provide a method for improving drought tolerance of a plant using the metabolite. A method for producing a metabolite capable of improving drought tolerance using a microorganism, said method comprising culturing a microorganism that belongs to the genus Collimonas and has an ability of producing a metabolite capable of improving drought tolerance of a plant and then extracting the metabolite from a culture produced by the culturing.Type: ApplicationFiled: February 10, 2015Publication date: February 1, 2018Applicants: New Environmental Technology Council, Kinki UniversityInventors: Takashi ANO, Yoichiro HIROSE
-
Patent number: 9828406Abstract: The invention is intended to provide an excellent antitumor agent. An antitumor agent contains a glycolipid glycoside compound represented by Formula (1) or a pharmacologically acceptable salt thereof as an active ingredient: in the formula, R1 to R4 are the same as or different from each other and represent an alkanoyl group or a hydrogen atom, and A represents a sugar alcohol residue or a polyol residue.Type: GrantFiled: May 28, 2012Date of Patent: November 28, 2017Assignee: KINKI UNIVERSITYInventors: Reiko Sugiura, Osamu Muraoka, Nozomi Tsutsui, Ayako Kita, Tatsuki Kunoh
-
Patent number: 9808401Abstract: Provided is an exposure-preventing cap of a novel and simple structure that, by being mounted on a vial, can more reliably inhibit leaking of drug solution to an outside when pulling out and collecting drug solution in a syringe from the vial. An exposure-preventing cap, which is mounted on a mouth of a vial sealed with a rubber stopper, wherein a puncturing hole is formed in a center part of a cap-shaped housing that is attached to a mouth of the vial, and a rubber membrane is arranged at the puncturing hole so as to form an internal space between facing surfaces of the rubber membrane and the rubber stopper. The rubber membrane has a dome shape that is convex facing the rubber stopper.Type: GrantFiled: May 15, 2013Date of Patent: November 7, 2017Assignees: KINKI UNIVERSITY, GTO, LTD., NIPRO CORPORATIONInventors: Shunji Ishiwata, Atsushi Taga, Shozo Nishida, Ayako Kita, Reiko Sugiura, Hideki Fujita, Mitsuru Hasegawa
-
Patent number: 9725519Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains an antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.Type: GrantFiled: December 5, 2014Date of Patent: August 8, 2017Assignees: Kinki University, Link Genomics, Inc.Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
-
Publication number: 20170166654Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.Type: ApplicationFiled: October 19, 2016Publication date: June 15, 2017Applicants: Daiichi Sankyo Co. Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
-
Patent number: 9512075Abstract: The present invention provides compounds belonging to 3-acyloxyindole compounds or 3-acyl-4-hydroxycoumarin compounds, a tautomer or geometric isomer thereof, or a salt thereof and methods for producing the same, which compounds are useful as antibacterial agent and as therapeutic drugs against infectious diseases.Type: GrantFiled: October 17, 2013Date of Patent: December 6, 2016Assignees: OKAYAMA UNIVERSITY, MICROBIAL CHEMISTRY RESEARCH FOUNDATION, KINKI UNIVERSITYInventors: Teruhiko Ishikawa, Tatsuya Kitaoka, Shyota Katayama, Yoshikuni Itoh, Ryutaro Utsumi, Masayuki Igarashi
-
Publication number: 20160345587Abstract: A method for producing a cell extract having agricultural pest insecticidal capacity by culturing filamentous fungi having insecticidal capacity for an agricultural pest, and a method for insecticide produced by this production method. A method for producing a cell extract having agricultural pest insecticidal capacity provided with a step for culturing filamentous fungi in solid medium and obtaining a solid culture of the filamentous fungi, a step for culturing the filamentous fungi in liquid medium and obtaining a liquid culture of the filamentous fungi, a step for separating mycelia of the filamentous fungi from the liquid culture of the filamentous fungi, a step for mixing the liquid culture from which the mycelia have been removed and the solid culture and obtaining a mixed culture, and a step for extracting a spore solution of the filamentous fungi from this mixed culture.Type: ApplicationFiled: February 10, 2014Publication date: December 1, 2016Applicants: Towada Green Tuff Agro-science Co., Ltd., Kinki UniversityInventors: Takashi ANO, Yoichiro HIROSE
-
Publication number: 20160326165Abstract: The present invention provides a hemiacetal ester prodrug of the pyridone carboxylic acid antibacterial drug, wherein the prodrug is characterized in that, (i) it is hydrolyzed promptly after intestinal absorption and regenerates the pyridone carboxylic acid antibacterial drug as a drug substance, (ii) a one-dose package is possible by preventing chelate-formation in intestines in an oral administration, and (iii) the normal bacterial flora of the intestinal bacterial flora is not influenced at all until the ester is absorbed, because the hemiacetal-type esterification is executed on the carboxylic acid which is a center of the antibacterial action, resulting in prevention of the pseudomembranous colitis. The prodrug is an alkoxy carbonyl hemiacetal-type ester represented by the chemical formula (I), which is useful as a prodrug for inhibiting the enteric-bacterium-shift side effect, and can be used in combination with polyvalent metal-containing medicines.Type: ApplicationFiled: December 18, 2014Publication date: November 10, 2016Applicants: KINKI UNIVERSITY, EDUCATIONAL CORPORATION MUKOGAWA GAKUIN, NIPRO CORPORATIONInventors: Kenji MATSUYAMA, Toru OTORI, Tetsutaro KIMACHI
-
Publication number: 20160194601Abstract: Provided are a novel cultivation method and a storage method that are suitable for storing bacteria belonging to the genus Collimonas for a long period of time. The cultivation method for bacteria belonging to the genus Collimonas is characterized in that bacteria belonging to the genus Collimonas are cultivated in a sealed state on a culture medium that includes a rice bran culture medium and/or a soy pulp culture medium. The storage method for bacteria belonging to the genus Collimonas is characterized in that the cultivated bacteria belonging to the genus Collimonas are stored at room temperature.Type: ApplicationFiled: September 4, 2013Publication date: July 7, 2016Applicants: NEW ENVIRONMENTAL TECHNOLOGY COUNCIL, KINKI UNIVERSITYInventors: Takashi ANO, Yoichiro HIROSE
-
Publication number: 20160175127Abstract: The present invention relates to a nanoparticle composition which is prepared by a process which is characterized by dissolving a poorly water-soluble compound or the like under a high temperature and a high pressure, and milling a suspension or the like containing a uniform crystal obtained by cooling the obtained solution.Type: ApplicationFiled: August 7, 2014Publication date: June 23, 2016Applicants: KINKI UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.Inventor: Yoshimasa ITO
-
Publication number: 20160121152Abstract: There are provided an anticancer agent degradation method for protecting medical professionals from exposure to an anticancer agent externally scattered in, for example, a safety cabinet or prescription laboratory, during drug preparation or other circumstance, and an anticancer agent degradation apparatus for use with this anticancer agent degradation method. Anticancer agent flyoff in a safety cabinet, etc. is degraded by exploiting an action of ozone-containing air humidified by humidifying means. A relative humidity of humidified ozone-containing air is preferably greater than or equal to 80%. In controlling degradation treatment on the basis of CT values, a difference between expected humidity and measured humidity is reflected in an increment of CT value to understand the progress of anticancer agent degradation properly.Type: ApplicationFiled: June 18, 2014Publication date: May 5, 2016Applicants: TAMURA TECO CO., LTD., KINKI UNIVERSITYInventors: Kozo Tamura, Yoshiyuki Fukuda, Shunji Ishiwata, Atsushi Taga
-
Publication number: 20160010070Abstract: The present invention provides a method for introducing a gene into Euglena, which can stably maintain a foreign gene, and a transformant therefrom. In this method of introducing a gene into Euglena, a DNA fragment containing an amino acid sequence for encoding a protein is introduced into a Euglena cell. The method includes a step of producing a binary vector containing a DNA fragment, a step of obtaining a linear gene fragment that includes a T-DNA region including the DNA fragment in the binary vector, and a direct gene introduction step of directly introducing the linear gene fragment into the Euglena cell.Type: ApplicationFiled: February 28, 2014Publication date: January 14, 2016Applicants: KINKI UNIVERSITY, EUGLENA CO., LTD.Inventors: Shigeru SHIGEOKA, Masahiro TAMOI, Kengo SUZUKI, Eriko YOSHIDA